Recent developments highlight Milestone Pharmaceuticals’ regulatory and commercial progress with etripamil, including FDA approval, commercial launch, and international regulatory review, alongside financial transactions supporting its operations.

• Milestone Pharmaceuticals launched CARDAMYST, the first self-administered FDA-approved nasal spray therapy for PSVT in January 2026 [N2].
• The FDA approved CARDAMYST in December 2025, marking a milestone as the first self-administered nasal spray treatment for PSVT [N6][N7].
• The company’s etripamil nasal spray was accepted by the European Medicines Agency (EMA) for review shortly after FDA approval [N3].
• Wells Fargo and HC Wainwright & Co. maintained positive recommendations on Milestone Pharmaceuticals in December 2025 [N4][N5].
• Milestone completed a $75 million royalty purchase agreement with RTW Investments in January 2026, providing upfront capital in exchange for future royalties on U.S. sales [S1].
• The company issued a pre-market earnings report for March 20, 2026, providing updates on financial results and commercial progress [N1].

Milestone Pharmaceuticals has achieved a significant regulatory milestone with FDA approval and commercial launch of CARDAMYST, the first self-administered nasal spray for PSVT, positioning it as a pioneer in this treatment modality. The licensing agreement for China and related territories and the royalty purchase agreement provide financial resources and potential revenue streams. Strong liquidity as of the end of 2025 supports ongoing operations and commercialization efforts. Continued regulatory approvals, successful market adoption, and effective management of supply chain and pricing risks could enhance the company’s business visibility and operational execution.

Milestone Pharmaceuticals faces substantial risks including dependency on a single product candidate, etripamil, with uncertain regulatory and commercial outcomes. The company reported a significant net loss in 2025 and relies on third-party manufacturers, some of which are located internationally, exposing it to supply chain disruptions and trade policy risks. Regulatory approval processes remain complex and may require additional clinical trials or impose labeling restrictions. Healthcare legislative reforms and drug pricing pressures in the U.S. and abroad could limit market access and profitability. These factors contribute to execution and financial risks that may adversely impact the company’s business and prospects.

Milestone Pharmaceuticals’ moat is primarily based on its proprietary nasal spray formulation of etripamil, which is the first FDA-approved self-administered treatment for PSVT. This regulatory milestone provides a competitive advantage in a niche therapeutic area with limited alternatives. The company’s licensing agreement for exclusive rights in China and related territories extends its geographic reach. However, the reliance on third-party manufacturing and the early commercial stage of its product limit the moat’s breadth. The company’s ability to maintain regulatory compliance, manage supply chain complexities, and navigate healthcare pricing reforms will be critical to sustaining its competitive position.

• Regulatory Approval Risks: Milestone’s future success depends on obtaining and maintaining regulatory approvals for etripamil. The FDA has requested additional information and inspections, and there is no assurance of approval. Regulatory delays or requirements for further clinical trials could adversely affect commercialization timelines and costs.
• Supply Chain and Trade Policy Risks: The company relies on third-party manufacturers and suppliers, including those outside the U.S. in countries such as China. International trade policies, tariffs, and geopolitical tensions may increase costs, disrupt supply chains, and complicate compliance, potentially delaying development and commercialization.
• Healthcare Legislative and Pricing Risks: Changes in U.S. healthcare laws, drug pricing regulations, and reimbursement policies, including Medicare Drug Price Negotiation and state drug importation programs, may reduce demand or pricing for etripamil, impacting revenue potential.
• Financial and Operational Risks: Milestone reported a net loss of $63.1 million in 2025 and depends on external financing and royalty monetization agreements. Execution risks include managing commercialization, regulatory compliance, and market adoption in a competitive and evolving healthcare environment.

• Milestone Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of etripamil, a nasal spray product for the treatment of paroxysmal supraventricular tachycardia (PSVT).
• The company’s lead and currently only product candidate, etripamil, received FDA approval as the first-ever self-administered nasal spray treatment for PSVT, marketed under the brand name CARDAMYST.
• Milestone launched CARDAMYST commercially following FDA approval in December 2025.
• Etripamil is manufactured in the United States, but several suppliers, including those providing active pharmaceutical ingredients (APIs), are located outside the U.S., including China.
• The company relies on third-party manufacturers and does not own or operate manufacturing facilities.
• Milestone entered into a license and collaboration agreement granting exclusive rights for etripamil nasal spray delivery in China and related territories to Corxel, affiliated with RTW Investments.
• The company completed a $75 million royalty purchase agreement with RTW Investments, receiving upfront funds in exchange for future royalty payments on U.S. net sales of etripamil.
• As of December 31, 2025, Milestone had $73.0 million in cash and equivalents and $32.9 million in short-term investments, with a current ratio of 8.01 and a cash ratio of 7.58, indicating strong liquidity.
• For the fiscal year ended December 31, 2025, the company reported a net loss of $63.1 million and basic and diluted EPS of -$0.75 per share.
• The company faces risks related to international trade policies, tariffs, and supply chain complexity due to reliance on foreign suppliers and geopolitical uncertainties.
• Regulatory risks include the lengthy and uncertain FDA approval process, potential additional clinical trial requirements, and changes in healthcare legislation and drug pricing policies.
• Milestone is subject to U.S. healthcare reform impacts, including Medicare Drug Price Negotiation Program and state-level drug importation programs, which may affect pricing and demand for etripamil.
• The company actively monitors risks related to trade restrictions, regulatory compliance, and healthcare policy changes that could materially affect its business and financial condition.